AirSculpt Technologies, Inc. (AIRS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights positive debt reduction and a strengthened balance sheet, but flat revenue growth and increased customer acquisition costs are concerns. The guidance for revenue and EBITDA shows modest growth expectations, and the Q&A indicates reliance on marketing strategies for improvement. The absence of new center openings and uncertainties in refinancing and macroeconomic conditions add risks. These mixed signals suggest a neutral stock price movement over the next two weeks.
Key Financial Performance
Revenue $39.4 million, flat versus the prior year quarter and up 1% on a same-store basis, excluding the impact of London. Same-store revenue growth was driven by higher case volume. This also reflects a 19% sequential improvement.
Gross Margin 60% of revenue, an expansion of roughly 1% compared to the prior year. This was achieved despite increased investments in marketing and brand development.
Selling, General and Administrative Expenses $22.6 million, an increase of approximately $800,000 compared to the prior year. This reflects deliberate investments in marketing and brand development.
Customer Acquisition Cost $3,400 per case, compared to $3,130 in the prior year quarter. The increase is attributed to enhanced marketing efforts.
Adjusted EBITDA $3.3 million or roughly 8.4% of revenue, a decrease from 9.5% in the prior year. This decline is due to increased investments in marketing and brand development.
Cash $16.7 million as of March 31, 2026. This reflects a strengthened balance sheet.
Debt Reduction $11 million of debt paid down in the quarter, resulting in gross debt outstanding of approximately $46 million at quarter end. Leverage reduced to below 2.5x, a reduction of over a turn compared to the same time last year.
Cash Flow from Operations Approximately $5 million for the quarter, compared to approximately $1 million in 2025. This improvement reflects better operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Services for GLP-1 Market: Introduced procedures like stand-alone skin tightening and skin removal to address side effects of GLP-1 medications. Completed over 150 skin excision procedures in Q1, with potential to unlock over $100 million in long-term revenue.
GLP-1 Market Opportunity: GLP-1 user base expected to grow from 5 million in 2023 to 25 million by 2030, creating a significant opportunity for body contouring in a $200 billion market.
Revenue Stabilization: Revenue for Q1 2026 was $39.4 million, flat year-over-year, with a 1% increase in same-store sales excluding London.
Gross Margin Expansion: Gross margin expanded to 60% of revenue, driven by higher case volume and cost discipline.
Debt Reduction: Paid down $11 million of debt in Q1, reducing leverage below 2.5x. Total debt outstanding is $46 million.
Sales and Marketing Enhancements: Improved digital funnel, expanded media mix, and better sales execution led to higher quality leads, improved conversion rates, and revenue growth.
Financial Discipline: Maintained cost discipline while strategically investing in marketing and brand development to drive long-term shareholder value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Debt Levels and Refinancing: The company has a gross debt of approximately $46 million and is in the process of refinancing its term loan. While progress is being made, the refinancing process introduces financial uncertainty and potential risks related to interest rates or unfavorable terms.
Customer Acquisition Costs: Customer acquisition costs increased to $3,400 per case from $3,130 in the prior year quarter. Rising costs could impact profitability if not managed effectively.
Macroeconomic Environment: The company is monitoring broader macroeconomic factors, including consumer sentiment, which could impact demand for its services. Economic uncertainties may pose risks to revenue growth.
Revenue Growth Dependency: The company’s revenue growth is heavily reliant on new procedures and marketing strategies. If these initiatives fail to deliver expected results, it could adversely affect financial performance.
Regulatory Compliance: The company must comply with various regulatory requirements, including those related to its credit agreement covenants. Non-compliance could lead to financial penalties or operational disruptions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Introducing new services to capture GLP-1 market opportunity: GLP-1 medications are reshaping the aesthetics landscape, with the user base expected to grow from 5 million in 2023 to 25 million by 2030. This creates a significant opportunity for body contouring, with nearly 19 million potential patients. AirSculpt is addressing this market with minimally invasive procedures, including new offerings like stand-alone skin tightening and skin removal. These procedures have the potential to unlock over $100 million in long-term revenue across existing centers.
Enhancing sales and marketing strategy: Marketing initiatives launched in late 2025 are driving consistent demand. Expanded media mix, influencer engagement, and targeted campaigns are improving lead quality and conversion rates. Sales execution has improved through better training and aligned incentives, contributing to revenue growth.
Maintaining strong financial discipline: Debt reduction remains a priority, with nearly $30 million repaid over the last 5 quarters. Leverage is now below 2.5x, and the company is in the process of refinancing its term loan. These efforts aim to strengthen the financial position and support long-term growth.
Full Year 2026 Financial Outlook: Revenue is expected to range between $151 million and $157 million, with adjusted EBITDA projected between $15 million and $17 million. Comparable revenue growth is anticipated at approximately 3%, excluding the London center. No new centers (de novos) are included in this guidance.
Second Quarter 2026 Expectations: Sequential improvement in both revenue and EBITDA is expected in Q2, which is a seasonally stronger quarter. The company aims to build on the positive momentum from Q1.
Long-Term Growth Strategy: The company is focused on disciplined execution and monitoring macroeconomic factors, including consumer sentiment, to adapt as conditions evolve. The initiatives in place are expected to provide a solid platform for sustained growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What has been working well in Q1, and how much of the improvement can be attributed to the enhanced marketing strategy, new skin tightening services, or a better demand environment for body contouring procedures?
A:The improvement in Q1 is primarily attributed to the enhanced marketing strategy, which has positively impacted leads, consults, and revenue. The new skin tightening services are still in the pilot phase and have not yet been a significant contributor. The consumer environment remains challenging, but the foundational work done in 2025 is driving growth, with more upside expected as new procedures expand.
Q:With the strengthened balance sheet, is there an opportunity to open new de novo centers later this year, or is that more likely in 2027?
A:The company does not plan to open any de novo centers in 2026. The focus remains on improving same-center sales growth, which is the top priority. While opening new centers is a long-term opportunity, it is not currently planned for this year.
Q:Review of Unclear Management Responses
A:No questions were avoided or lacked clarity in the responses provided by management.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AirSculpt differentiation
AirSculpt solution
Cost discipline
Customer acquisition
Debt reduction
GLP market
GLP user
ICR today
London store
Malkin Partner
Partner ICR
Sales training
Selling increase
Technologies reminder
Today industry
ability term
action fruit
base increase
basis London
body
center sale
investment marketing
loan detail
need
place
priority momentum
procedure skin
quarter
reduction turn
sale marketing
service GLP
sheet cash
skin removal
start momentum
term loan
tightening skin
value
AIRS Transcript
AirSculpt Technologies, Inc. (AIRS) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call highlights positive debt reduction and a strengthened balance sheet, but flat revenue growth and increased customer acquisition costs are concerns. The guidance for revenue and EBITDA shows modest growth expectations, and the Q&A indicates reliance on marketing strategies for improvement. The absence of new center openings and uncertainties in refinancing and macroeconomic conditions add risks. These mixed signals suggest a neutral stock price movement over the next two weeks.
AirSculpt Technologies, Inc. (AIRS) Q4 2025 Earnings Call Transcript
Unknown4-2
The earnings call reveals significant challenges: a 15% revenue decline, financial control issues, and a high debt level. Although there is some margin expansion and positive signs in body sculpting trends, the overall financial health is concerning. The Q&A section suggests cautious optimism for future revenue but lacks strong positive catalysts. Given these factors, the stock is likely to experience a negative reaction in the short term.
AirSculpt Technologies, Inc. (AIRS) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents a negative outlook, with reduced revenue guidance, declining financial performance, and high leverage limiting flexibility. Despite some cost-cutting measures, the revenue and EBITDA have decreased, and the company faces challenges with new services. The Q&A highlighted uncertainties in cost savings and service expansion, with management providing vague responses. Given these factors, a negative stock price movement is likely, reflecting the company's current financial struggles and market uncertainties.
AirSculpt Technologies, Inc. (AIRS) Q2 2025 Earnings Call Transcript
Unknown8-1
The earnings call summary shows a challenging macro environment with a decline in same-store revenue and cases, despite some cost reductions and improved cash flow. The Q&A section highlights consumer hesitancy, uncertainty in revenue guidance, and lack of clear data on new initiatives like skin tightening. The leverage ratio improvement is positive, but overall, weak financial performance and guidance uncertainty suggest a negative sentiment.
AIRS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
